한글목차

세계의 레날리도마이드(Lenalidomide) 시장의 미래에는 다발성 골수종과 골수이형성 증후군 시장 기회가 유망시되고 있습니다. 2025년부터 2031년까지 연평균 5%의 성장률로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 혈액암의 유병률 상승, 표적 치료의 채택 확대, 일반 옵션의 가용성 증가입니다.

• Lucintel사의 예측에서는 유형별로는 25mg 캡슐이 예측 기간 중에 가장 높은 성장을 이룰 전망입니다.
• 용도별로는 다발성 골수종이 높은 성장을 이룰 것으로 예측되고 있습니다.
• 지역별로는 북미가 예측기간 중에 가장 높은 성장이 예상됩니다.

레날리도마이드(Lenalidomide) 시장의 새로운 동향

레날리도마이드(Lenalidomide) 시장은 성장 경로를 결정하는 새로운 동향에 의해 극적인 변화에 직면하고 있습니다.

• 병용요법의 중시 : 레날리도마이드(Lenalidomide)나 다른 항암제와의 병용요법이 시장에서 점점 보급되고 있습니다. 연구에 따르면 이러한 조합은 치료 결과를 개선하여 환자에게 보다 표적화되고 효과적인 치료를 제공합니다. 병용 요법을 지지하는 임상 근거가 증가하고 있기 때문에 이러한 치료의 일환으로서 레날리도마이드(Lenalidomide)의 사용이 증가해, 그 결과, 시장의 성장이 개선한다고 생각됩니다.
• 바이오시밀러 도입 : 레날리도마이드(Lenalidomide) 마켓플레이스에 바이오시밀러가 등장해 게임 체인저가 되는 것이 증명되고 있습니다. 브랜드 이름보다 저렴한 바이오시밀러는 지출을 줄이고 새로운 소비자에게 시장을 개방할 것을 약속했습니다. 특히, 중국이나 헬스케어 등 의료 수요가 증가하고 있는 지역에서는 이러한 경향이 현저합니다.
• 새로운 적응증에 대한 규제 당국의 승인 : FDA, EMA, NMPA 등의 규제 기관은 레날리도마이드(Lenalidomide)의 적응을, 특히 혈액 악성 종양의 치료에 대해 확대하고 있습니다.
• 환자 접근의 중요성 : 많은 국가에서 약물의 가격과 건강 보험이 여전히 문제가 되었기 때문에 환자에 대한 액세스가 중심적인 과제가되고 있습니다. 향상을 위해 정부와 가격 협상을 실시했습니다.인도나 중국 등의 신흥국에서는 제네릭 의약품이나 바이오시밀러에 의한 유통망의 확대나 코스트 삭감이, 접근성 향상의 열쇠가 됩니다.
• 새로운 암 치료제의 상승 : 레날리도마이드(Lenalidomide) 시장은 표적 치료제와 면역 요법과 같은 새로운 암 치료제에 의해 점점 위협을 받고 있습니다. 레날리도마이드(Lenaridomide)는 시장 점유율을 유지하는 데 어려움을 겪을 수 있습니다.

이러한 동향으로부터, 기술 개발, 규제 상황, 소비자 요구의 변화에 의해 재정의되고 있는 진화하고 있는 레날리도마이드(Lenalidomide) 시장에 주목이 모여 있습니다. 시장 경쟁은 바이오시밀러의 등장에 의해 격화하고 있습니다만, 한편으로 병용 요법이나 환자 액세스의 중시가 성장을 가속할 것입니다. 새로운 치료법과 가격 문제는 이러한 성장 추세를 유지하기 위해 극복해야 할 과제입니다.

레날리도마이드(Lenalidomide) 시장의 최근 동향

레날리도마이드(Lenalidomide) 시장은 그 미래를 좌우하는 몇 가지 큰 시장 개척을 목격해 왔습니다.

• 적응 확대를 위한 FDA 승인 미국 식품의약국(FDA)은 레날리도마이드(Lenalidomide)의 적응을 확대하고, 특히 다발성 골수종 등의 혈액암에의 적응을 확대했습니다.
• 레날리도마이드(Lenalidomide) 바이오시밀러의 도입 : 레날리도마이드(Lenalidomide) 바이오시밀러의 발매는 특히 인도나 중국 등 시장에 있어서 큰 사건이었습니다.
• 세계 시장의 확대 : 레나리도마이드는 인도나 중국 등의 신흥국에서 급속히 시장이 확대되고 있습니다.
• 레날리도마이드(Lenalidomide) 병용 요법의 조사: 레날리도마이드(Lenalidomide)와 다른 암 치료제와의 병용에 관한 조사가 진행 중입니다.
• 비용 압력과 가격 협상 : 레날리도마이드(Lenalidomide) 시장에서는 특히 국영 헬스케어 시스템을 가진 국가들로부터의 비용 압박이 여전히 중요한 과제가 되고 있습니다.

이러한 진보는 특히 신흥국 시장과 바이오시밀러 등 보다 비용 효율적인 대체품의 등장으로 레날리도마이드(Lenalidomide) 시장의 확대에 박차를 가하고 있습니다.

목차

제1장 주요 요약

제2장 세계의 레날리도마이드(Lenalidomide) 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 레날리도마이드(Lenalidomide) 시장 동향(2019-2024년)과 예측(2025-2031년)
• 유형별
  • 5mg 캡슐
  • 10mg 캡슐
  • 15mg 캡슐
  • 25mg 캡슐
• 용도별
  • 다발성 골수종
  • 골수이형성증후군

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 지역별
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 유형별
  • 용도별
  • 지역별
• 세계의 레날리도마이드(Lenalidomide) 시장에서의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 레날리도마이드(Lenalidomide) 시장의 생산 능력 확대
  • 세계의 레날리도마이드(Lenalidomide) 시장에서의 합병, 인수, 합작 사업
  • 인증 및 라이선싱

제7장 주요 기업의 기업 프로파일

• Celgene
• SL Pharma
• Dr. Reddy's Laboratories
• Cipla
• Delphis Pharma

영문목차

The future of the global lenalidomide market looks promising with opportunities in the multiple myeloma and myelodysplastic syndrome markets. The global lenalidomide market is expected to grow with a CAGR of 5% from 2025 to 2031. The major drivers for this market are the rising prevalence of hematological cancers, the growing adoption of targeted therapies, and the increasing availability of generic options.

• Lucintel forecasts that, within the type category, 25 mg capsule is expected to witness the highest growth over the forecast period.
• Within the application category, multiple myeloma is expected to witness higher growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Lenalidomide Market

The lenalidomide market is facing drastic changes with emerging trends that determine its growth path. These trends are driven by advances in biotechnology, regulatory changes, and consumer behavior changes. The following are the most important emerging trends affecting the market:

• Greater Emphasis on Combination Therapies: Combination therapies with lenalidomide and other cancer drugs are becoming increasingly popular in the market. Studies indicate that these combinations improve treatment outcomes, providing more targeted and effective treatments for patients. With increasing clinical evidence favoring combination treatments, the use of lenalidomide as part of these treatments is likely to increase, resulting in improved market growth.
• Introduction of Biosimilars: The emergence of biosimilars into the lenalidomide marketplace is proving to be a game changer. Biosimilars, which cost less than brand names, promise to reduce expenditures and open the marketplace to new consumers. Such is the pattern, especially being witnessed in parts of the world where healthcare demands are increasing, like China and India. Biosimilars may keep costs down but create competition for currently established brands too.
• Regulatory Approvals for New Indications: Regulatory agencies like the FDA, EMA, and NMPA are broadening lenalidomide's indications, especially for the treatment of hematologic malignancies. As more clinical trials prove its efficacy in other indications, lenalidomide is being approved for wider usage, opening up new market segments and increasing its uptake globally.
• Emphasis on Patient Accessibility: Patient access is taking center stage with drug affordability and healthcare coverage still issues in many countries. Firms are launching patient support programs and price negotiations with governments to enhance access. In emerging economies such as India and China, increasing distribution networks and decreasing costs through generics and biosimilars will be key to enhancing accessibility.
• New Cancer Therapies Compete Emerging: The lenalidomide market is increasingly threatened by newer cancer therapies, such as targeted therapies and immunotherapies. As the cancer treatment landscape continues to shift, lenalidomide could struggle to hold onto its market share. Pharmaceutical companies are looking to differentiate their products through enhanced formulations and clinical benefits to maintain competitive edge.

These trends put the ever-evolving lenalidomide market in focus, where technological development, regulatory action, and changing consumer needs are redefining the landscape. The competition in the market is increasing due to the inclusion of biosimilars, whereas greater emphasis on combination therapies and patient access should encourage growth. New therapies and pricing issues are challenges that should be overcome in order to maintain this growth trend.

Recent Developments in the Lenalidomide Market

The lenalidomide market has witnessed some major developments that are determining its future. They include regulatory approvals, generics, new indications, and expansion into global markets. The following are the significant developments that are affecting the market:

• FDA Approvals for Expanded Indications: The U.S. Food and Drug Administration (FDA) has broadened the indications for lenalidomide, specifically for blood cancers such as multiple myeloma. These approvals have opened the door to wider use in the treatment of blood cancers, and lenalidomide is now an essential part of cancer treatment regimens.
• Introduction of lenalidomide Biosimilars: Launching lenalidomide biosimilars has been a major event in the market, particularly in markets such as India and China. These cheaper alternatives are likely to lower the cost of treatment and enhance access to patients, hence growing the drug's market penetration.
• Global Market Expansion: Lenalidomide has witnessed high-speed market growth in emerging nations such as India and China. The availability of lenalidomide in these markets has created new markets, especially for the use of multiple myeloma. With the advancement of healthcare infrastructure, the accessibility of the drug is likely to increase substantially.
• lenalidomide Combination Therapies Research: Research on combining lenalidomide with other cancer treatments is on the horizon. Thus far, this combination has demonstrated potential for enhancing the potency of the treatments, especially in relapsed/refractory multiple myeloma. The success of such combinations in the clinic may further accelerate the use of lenalidomide in cancer treatment.
• Cost Pressure and Pricing Negotiations: Cost pressure remains a key challenge in the lenalidomide market, particularly from countries with a nationalized system of healthcare. Governments and insurances are making price negotiations with drug companies for the drug to be more cost-effective. It may result in the drug's availability at low prices, thus enhancing patient accessibility.

These advancements are fueling the expansion of the lenalidomide market, particularly in developing countries and with the advent of more cost-effective substitutes such as biosimilars. As the medication is approved for additional indications and combination therapies, its distribution expands even further worldwide.

Strategic Growth Opportunities in the Lenalidomide Market

The lenalidomide market offers a number of strategic growth opportunities through various applications, mainly in the treatment of cancer. With the evolving market, new possibilities arise based on shifting patient needs, healthcare systems, and treatment paradigms.

• Growth into New Geographies: Increasing the access of lenalidomide to growing economies like China and India offers great growth opportunities. With developing healthcare systems and an increase in the demand for oncology treatments, firms are able to access these markets for increased penetration. Adjusting pricing strategies to be affordable will be the fulcrum in these markets.
• Development of lenalidomide Biosimilars: With the introduction of lenalidomide biosimilars, drug manufacturers have a special chance to reach the increasing market for cost-effective cancer treatment. Biosimilars ensure quality care while offering an economic alternative, thus passing on the savings to patients. This presents a tremendous market expansion opportunity in price-sensitive markets.
• Investment in Clinical Trials for New Indications: Broader application of lenalidomide from its existing indications, including determining the potential use for other cancer treatment, holds enormous growth value. Clinical trials of its potential combination therapy uses also have potential for future market growth, situating lenalidomide as a convenient choice in cancer oncology treatment.
• Increased Patient Assistance Programs: Expanding and developing patient support programs, especially in the developing world, is a potential opportunity to maximize market access. This approach will make lenalidomide more accessible to underserved patient populations, which will increase both sales and patient satisfaction, as well as foster long-term growth in the market.
• Emphasis on Innovative Formulations: The drug manufacturers can research new forms of lenalidomide, like extended-release or combination drugs. The new forms can improve treatment outcomes and patient compliance, leading to increased market acceptance and positioning lenalidomide as a more inclusive treatment approach.

These strategic growth areas point out main areas in which the lenalidomide market can grow, such as new markets in geography, biosimilars, clinical innovations, patient access programs, and improved formulations. Adopting these opportunities will be essential for ensuring long-term growth in the market.

Lenalidomide Market Driver and Challenges

The lenalidomide market is impacted by a variety of technological, economic, and regulatory forces. Identifying these drivers and challenges is crucial for foretelling market change and determining areas of growth. Listed below are the most significant drivers and challenges impacting the market.

The factors responsible for driving the lenalidomide market include:

1. Growing Cancer Incidence: The rising global incidence of cancer, including blood cancers like multiple myeloma, is one of the major drivers for the lenalidomide market. As diagnosis rates continue to grow, so does demand for effective treatment such as lenalidomide, thus promoting market growth.

2. Technological Innovation in Drug Discovery: Biotechnology and drug development advancements are facilitating the improvement in the efficacy of lenalidomide, especially when utilized in combination treatments. The advances enhance patient benefits and broaden the application of the drug across many types of cancers, thereby enhancing demand.

3. Regulatory Assistance to Oncology Drugs: Regulators such as the FDA, EMA, and NMPA have assisted in favorable guidelines for the approval and utilization of lenalidomide that allow its general usage in treating blood cancers. Such regulatory assistance enables ease in access and uptake.

4. Increasing Healthcare Spend: In most nations, escalating healthcare spending is making it easier for people to gain access to cancer therapies like lenalidomide. The market growth is being accelerated by increased financing by the government and private enterprise, especially in advanced economies.

5. Approval of lenalidomide Biosimilars: Launching biosimilars in the lenalidomide market presents opportunities for increased treatment access and reduced prices. As the biosimilars gain regulatory approval, competition and patient access to cost-effective treatments will increase.

Challenges in the lenalidomide market are:

1. High Treatment Costs: Lenalidomide is still very costly, especially in regions that lack universal healthcare. Drug costs are a barrier to treatment access, which constrains the size of the potential market, especially in less affluent regions.

2. Regulatory and Market Access Barriers: Even in the presence of favorable regulatory environments, access to lenalidomide remains problematic in some markets, most notably because of protracted approval processes or outright bans on reimbursement. Such regulatory hurdles can delay market penetration in target markets.

3. Emerging Competition: lenalidomide faces increasing competition from newer therapies, including targeted treatments and immunotherapies, which may offer better efficacy or fewer side effects. This competition may limit lenalidomide's market share in the long run.

Incidence drivers of increased cancer, technological advancement, and regulations are driving growth in the lenalidomide market. However, limitations posed by high treatment prices, regulatory hurdles, and upcoming competition may hamper the realization of full market potential. Solutions for these problems will be essential for maintaining growth.

List of Lenalidomide Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies lenalidomide companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the lenalidomide companies profiled in this report include-

• Celgene
• SL Pharma
• Dr. Reddy's Laboratories
• Cipla
• Delphis Pharma

Lenalidomide Market by Segment

The study includes a forecast for the global lenalidomide market by type, application, and region.

Lenalidomide Market by Type [Value from 2019 to 2031]:

• 5 mg capsules
• 10 mg capsules
• 15 mg capsules
• 25 mg capsules

Lenalidomide Market by Application [Value from 2019 to 2031]:

• Multiple myeloma
• Myelodysplastic syndromes

Lenalidomide Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Lenalidomide Market

The lenalidomide market, fueled by its application to cure a host of cancers and blood disorders, has grown manifold over the recent past. Emerging as an immunomodulatory medication, lenalidomide is now an indispensable component of therapy to cure multiple myeloma as well as myelodysplastic syndromes (MDS). The growth of the market is due to its rising demand in key regions, such as the United States, China, Germany, India, and Japan. Regulatory barriers and pricing pressures are still present, however, and impact the direction of the market. Despite these issues, the market is still developing with encouraging developments and new indications.

• received FDA approval for a variety of conditions, particularly multiple myeloma. Recent milestones involve the approval of new combination regimens, adding to the drug's use in combination with other drugs to maximize effectiveness. The U.S. market is also directed towards increasing access via healthcare reforms and insurance coverage. The growing incidence of multiple myeloma, along with the expanding number of clinical trials exploring lenalidomide's applications in other malignancies, continues to drive its market expansion. Even at exorbitant prices, lenalidomide's integration into treatment protocols guarantees its leading status in the American healthcare system.
• China: In China, lenalidomide is also gaining momentum, especially as the country's healthcare infrastructure continues to develop and hematological cancers gain more awareness. lenalidomide has been listed under the National Reimbursement Drug List (NRDL), giving patients cheaper access. Chinese government approval for new indications in lenalidomide, e.g., to treat myelodysplastic syndromes, has also increased usage. Though the cost of the drug continues to be an issue, attempts at regulation and price standardization by the Chinese government have opened up access to the general public. Market for lenalidomide in China is anticipated to expand with the growing demand for cancer therapy.
• Germany: Germany possesses a well-established health system, and lenalidomide is extensively used to treat multiple myeloma and other forms of cancer. The approval of the drug for additional indications has helped to grow the market in Germany. The German health system's focus on evidence-based treatment means that lenalidomide's very high effectiveness in the treatment of multiple myeloma and related disorders is well established. Pricing pressures and reimbursement continue to be problematic, though, as lenalidomide is a costly drug. Germany's policy towards health technology assessment and reimbursement policies significantly influences its market penetration.
• India: In India, the market for lenalidomide has been growing, particularly with its growing presence in the private healthcare sector. The use of lenalidomide in treating multiple myeloma and other cancers is gaining more traction, supported by enhanced access to healthcare and government programs. Yet, affordability continues to be an issue, and most patients opt for generic forms of the drug, which lowers the cost burden. Indian market is experiencing higher cancer treatment awareness, which results in higher demand for efficient treatments such as lenalidomide. Government initiatives to enhance cancer care are also making the drug more accessible.
• Japan: Japan has a matured healthcare market, and lenalidomide is well established in the treatment of multiple myeloma. The market for lenalidomide in Japan is expanding as additional clinical trials and wider indications, including for the treatment of mantle cell lymphoma, become approved. The healthcare system in the country is very efficient, and patients are covered with extensive insurance for their lenalidomide therapies. Moreover, Japan's aging population with a rising incidence of cancers such as multiple myeloma is a strong force behind market expansion. Usage of lenalidomide in Japan will likely rise as more people are diagnosed and treated for various hematologic malignancies.

Features of the Global Lenalidomide Market

Market Size Estimates: Lenalidomide market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Lenalidomide market size by type, application, and region in terms of value ($B).

Regional Analysis: Lenalidomide market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the lenalidomide market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the lenalidomide market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the lenalidomide market by type (5 mg capsules, 10 mg capsules, 15 mg capsules, and 25 mg capsules), application (multiple myeloma and myelodysplastic syndromes), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Lenalidomide Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Lenalidomide Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Lenalidomide Market by Type
  • 3.3.1: 5 mg capsules
  • 3.3.2: 10 mg capsules
  • 3.3.3: 15 mg capsules
  • 3.3.4: 25 mg capsules
• 3.4: Global Lenalidomide Market by Application
  • 3.4.1: Multiple myeloma
  • 3.4.2: Myelodysplastic syndromes

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Lenalidomide Market by Region
• 4.2: North American Lenalidomide Market
  • 4.2.1: North American Market by Type: 5 mg capsules, 10 mg capsules, 15 mg capsules, and 25 mg capsules
  • 4.2.2: North American Market by Application: Multiple myeloma and Myelodysplastic syndromes
• 4.3: European Lenalidomide Market
  • 4.3.1: European Market by Type: 5 mg capsules, 10 mg capsules, 15 mg capsules, and 25 mg capsules
  • 4.3.2: European Market by Application: Multiple myeloma and Myelodysplastic syndromes
• 4.4: APAC Lenalidomide Market
  • 4.4.1: APAC Market by Type: 5 mg capsules, 10 mg capsules, 15 mg capsules, and 25 mg capsules
  • 4.4.2: APAC Market by Application: Multiple myeloma and Myelodysplastic syndromes
• 4.5: ROW Lenalidomide Market
  • 4.5.1: ROW Market by Type: 5 mg capsules, 10 mg capsules, 15 mg capsules, and 25 mg capsules
  • 4.5.2: ROW Market by Application: Multiple myeloma and Myelodysplastic syndromes

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Lenalidomide Market by Type
  • 6.1.2: Growth Opportunities for the Global Lenalidomide Market by Application
  • 6.1.3: Growth Opportunities for the Global Lenalidomide Market by Region
• 6.2: Emerging Trends in the Global Lenalidomide Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Lenalidomide Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Lenalidomide Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Celgene
• 7.2: SL Pharma
• 7.3: Dr. Reddy's Laboratories
• 7.4: Cipla
• 7.5: Delphis Pharma